Deals, Development and Manufacturing

Orgenesis has signed a co-development agreement with Accelix to integrate advanced optic technologies, cartridges, and software onto POCare platform.

GammaDelta Therapeutics has unveiled the formation of a new spin-out company, Adaptate Biotherapeutics, aimed at developing antibody-based therapies that modulate gamma delta T-cells.

Enterprise Therapeutics is the recipient of funding worth up to £5.7 million (US $7 million) from the Cystic Fibrosis Foundation.

The long-term agreement gives CombiGene the authority to manufacture and commercialize the drug if it is approved after clinical studies.

The transaction gives Alexion access to Achillion’s portfolio of oral small-molecule Factor D inhibitors to treat people with complement alternative pathway-mediated rare diseases.

Lonza, through its Ibex Solutions, will now cover preclinical and clinical development and manufacturing for a significant portion of Genmab’s pipeline.

The Italy-based pharmaceutical glass and plastic packaging manufacturer, announced it will be showcasing its prototypes for usability, sustainability, connectivity, and traceability.

As the world awaits the outcome of Brexit, a presentation taking place at CPhI Worldwide in Frankfurt, Germany will delve deeper into the implications of each potential scenario on the pharma industry.

The companies will collaborate to identify and develop in-vivo genome editing therapeutic candidates for genetic diseases, including hemophilia.

The collaboration aims to reduce “vein-to-vein” time for patients and to optimize manufacturing and supply operations.

The new location will handle logistics, development, data, service support, FAT, and project management.

MilliporeSigma will now be the first company to make acoustic technology available for cell therapy manufacturing.

The new device protects children from accidentally taking painkillers, antidepressants, or medical cannabis with a new opening mechanism.

The acquisition comes after Bormioli became an independent company owned by Triton Investment Fund in December 2017.

The collaboration focuses on baculovirus/Sf9 expression system for Prevail's pipeline of novel AAV9-based gene therapy programs neurodegenerative diseases.

Under a collaboration potentially worth more than $1.5 billion, the companies aim to develop the antisense therapy to treat patients with certain cardiovascular and metabolic diseases.

When the injector design is finalized, Stevanato Group will produce it at one of its manufacturing facilities using extensive tooling, molding, and assembly expertise.

GSK invested $139 million to its Rockville, MD site to support demand for Benlysta.

The companies are working together with Japanese clients to outline projects from early clinical stage up to commercial launch.

The new joint venture, named Oerth Bio, will use Arvinas’ Protac technology to develop innovative new agricultural products. As part of its collaboration with Arvinas, Bayer is also using this technology to develop human therapeutics.

Manufacturing of the cell line will take place at Lonza’s GMP facility in Geleen, Netherlands.

New therapies, new technologies, global supply chain challenges, and political pressures draw pharma professionals to major industry event.

Nanoform and AstraZeneca have agreed to start a technology evaluation of Nanoform’s CESS Technology across a range of AstraZeneca’s pharmaceutical products.

The companies plan to collaborate for the advancement of an optical system for on-line analysis of mammalian cells during a bioprocess.

The initiative looks to improve treatments for chronic pain, curb the rates of opioid use disorder (OUD) and overdose, and achieve long-term recovery from opioid addiction.

If clinical trials are successful, roluperidone (MIN-101) will be the first treatment approved to treat symptoms of schizophrenia in the United States.

The companies have advanced their collaboration to the next stage and will continue to develop a plant-based biosimilar candidate to Roche’s Rituxan.

Under a new co-development license agreement, Boehringer Ingelheim and Inflammasome Therapeutics aim to develop novel therapies for retinal diseases.

The companies will focus on identifying peptides applicable to the affinity chromatography process used in the purification of biopharmaceuticals.

The Committee for Medicinal Products for Human Use of the European Medicines Agency has granted a positive opinion recommending marketing authorization for Bavencio (avelumab) in combination with axitinib for treating kidney cancer.